SCHEDULE: Octagon Capital Discloses 3.8% Stake in Gossamer Bio

Octagon Capital Advisors LP, along with affiliated entities and Ting Jia, has reported beneficial ownership of 8,976,054 shares, representing 3.8% of Gossamer Bio, Inc.'s common stock.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia have jointly filed a Schedule 13G, indicating their beneficial ownership of Gossamer Bio, Inc. common stock.
• The total number of shares beneficially owned is 8,976,054, which constitutes 3.8% of the class of securities.
• This holding includes 7,750,000 common shares directly held and warrants to purchase an additional 1,226,054 common shares.
• The warrants have an exercise price of $2.04 per share and an expiration date of July 24, 2028.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports existing ownership and does not contain new operational or financial performance data that would significantly alter the investment thesis.

Positives

• Significant stake held by an investment advisor and its affiliated fund, suggesting confidence in the company's prospects.
• Warrants provide potential for increased ownership and upside if the stock price exceeds the exercise price.

Negatives

• The 3.8% stake is below the 5% threshold that typically triggers more detailed ownership disclosures, suggesting this is a passive investment at this stage.
• The filing does not provide specific financial performance data for Gossamer Bio, Inc., focusing solely on ownership.

Risks

• The exercise of warrants is contingent on the stock price reaching $2.04, which may not occur.
• Changes in investment strategy by Octagon Capital Advisors LP could lead to the sale of shares, potentially impacting the stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance from Gossamer Bio, Inc. The future outlook for the reporting persons is tied to the performance of Gossamer Bio, Inc. and the potential exercise of their warrants.

Management Comments

• Octagon serves as the investment manager of the Master Fund.
• Dr. Jia is the managing member of Octagon.
• Each of Octagon and Dr. Jia may be deemed to beneficially own the Issuer's Common Shares directly owned by the Master Fund.
• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors acquiring significant stakes in biotechnology companies. Gossamer Bio operates in the clinical-stage biopharmaceutical sector, which is characterized by high R&D costs and binary outcomes based on clinical trial results. This filing indicates a notable institutional interest, but the 3.8% stake suggests a passive investment rather than an activist position.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional holding, which can be viewed positively for stability, but the passive nature of the investment means it's unlikely to drive immediate strategic changes.
• Management: The reporting persons have certified that the shares are not held to influence control, indicating no immediate pressure on management from this specific filing.
• Creditors: No direct impact on creditors is indicated by this ownership filing.

Next Steps

• Monitoring Gossamer Bio, Inc.'s clinical trial progress and financial reports.
• Observing any future changes in Octagon Capital Advisors LP's ownership stake.

Key Dates

Keywords

Gossamer Bio, Schedule 13G, Octagon Capital Advisors LP, Octagon Investments Master Fund LP, Ting Jia, beneficial ownership, common stock, warrants, SEC filing